Ariad Expects Narrower Label, Not Withdrawal, For Iclusig Following Halted Study
Executive Summary
Company’s terminated EPIC trial in front-line leukemia was a post-marketing requirement under ponatinib’s accelerated approval for second-line treatment, but management believes FDA will favor a restricted label, rather than withdrawal, to address growing concerns about cardiovascular safety.